{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:29:46Z","timestamp":1786696186929,"version":"build-2736575974"},"reference-count":39,"publisher":"Walter de Gruyter GmbH","issue":"6","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-1169_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Accurate measurement of 17\u03b1-hydroxyprogesterone (17-OHP) in human serum and plasma is required for steroid profiling, to ensure the appropriate diagnosis of congenital adrenal hyperplasia. Therefore, an isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS\/MS)-based candidate reference measurement procedure (RMP) to quantify 17-OHP in human serum and plasma has been developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1169_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A two-dimensional heart-cut LC approach was used to minimize matrix effects and prevent co-elution of interferences. A post-column infusion experiment was conducted to assess the potential impact of different matrices on ion suppression or enhancement effects. A multi-day validation experiment assessed precision, trueness and accuracy. Measurement uncertainty was evaluated in compliance with current guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1169_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The working range of this RMP was 0.0200\u201360.0\u202fng\/mL (0.0605\u2013182\u202fnmol\/L) and the method proved to be matrix-independent. The intermediate precision coefficient of variation (CV) ranged from 1.5\u202f% to 2.1\u202f% and repeatability CV from 1.3\u202f% to 1.9\u202f%, across all concentration levels. The relative mean bias ranged from\u00a0\u22124.0\u202f% to 2.0\u202f%, regardless of the matrix and concentration level. The measurement process for single measurements showed an expanded uncertainty (k=2) between 3.6\u202f% and 4.5\u202f%. This uncertainty was further reduced performing the target value assignment (n=6), resulting in a range of 2.0\u20132.5\u202f%. Equivalence between the candidate RMP and the Joint Committee on Traceability in Laboratory Medicine-listed RMPs was established through participation in the External Quality Assessment scheme for reference Laboratories in Laboratory Medicine (RELA) ring\u00a0trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1169_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The performance of this procedure enables the evaluation and standardization of routine assays, and the evaluation of patient samples, to ensure traceability of individual patient results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-1169","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:57:11Z","timestamp":1773208631000},"page":"1355-1370","source":"Crossref","is-referenced-by-count":1,"title":["An isotope dilution-liquid chromatography-tandem mass spectrometry-based candidate reference measurement procedure for the quantification of 17-hydroxyprogesterone in human serum and plasma"],"prefix":"10.1515","volume":"64","author":[{"given":"Martina","family":"Bachmann","sequence":"first","affiliation":[{"name":"111618 Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Ott","sequence":"additional","affiliation":[{"name":"111618 Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Singh","sequence":"additional","affiliation":[{"name":"111618 Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Bauland","sequence":"additional","affiliation":[{"name":"Chrestos Concept GmbH & Co. KG , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"K\u00f6ppl","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine , University Hospital Erlangen , Erlangen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7197-3868","authenticated-orcid":false,"given":"Alexander","family":"Gaudl","sequence":"additional","affiliation":[{"name":"Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Geistanger","sequence":"additional","affiliation":[{"name":"111618 Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Ceglarek","sequence":"additional","affiliation":[{"name":"Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Rauh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine , University Hospital Erlangen , Erlangen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Taibon","sequence":"additional","affiliation":[{"name":"111618 Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026081408005182988_j_cclm-2025-1169_ref_001","doi-asserted-by":"crossref","unstructured":"Honour, JW. 17-Hydroxyprogesterone in children, adolescents and adults. Ann Clin Biochem 2014;51:424\u201340. https:\/\/doi.org\/10.1177\/0004563214529748.","DOI":"10.1177\/0004563214529748"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_002","doi-asserted-by":"crossref","unstructured":"Yoon, YA, Woo, S, Kim, MS, Kim, B, Choi, YJ. Establishing 17-hydroxyprogesterone cutoff values for congenital adrenal hyperplasia in preterm, low birth weight, and sick newborns. Exp Clin Endocrinol Diabetes 2023;131:216\u201321. https:\/\/doi.org\/10.1055\/a-2022-8399.","DOI":"10.1055\/a-2022-8399"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_003","doi-asserted-by":"crossref","unstructured":"Rosenfield, RL. Serum cortisol and 17-hydroxyprogesterone concentrations in children with classic congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2002;87:2993. https:\/\/doi.org\/10.1210\/jc.87.6.2993. author reply 2993.","DOI":"10.1210\/jcem.87.6.8555"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_004","doi-asserted-by":"crossref","unstructured":"Auer, MK, Nordenstr\u00f6m, A, Lajic, S, Reisch, N. Congenital adrenal hyperplasia. Lancet 2023;401:227\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(22)01330-7.","DOI":"10.1016\/S0140-6736(22)01330-7"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_005","doi-asserted-by":"crossref","unstructured":"Fraga, NR, Minaeian, N, Kim, MS. Congenital adrenal hyperplasia. Pediatr Rev 2024;45:74\u201384. https:\/\/doi.org\/10.1542\/pir.2022-005617.","DOI":"10.1542\/pir.2022-005617"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_006","doi-asserted-by":"crossref","unstructured":"Sarafoglou, K, Barnes, CN, Huang, M, Imel, EA, Madu, IJ, Merke, DP, et al.. Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies. J\u00a0Clin Endocrinol Metab 2021;106:e4666\u201379. https:\/\/doi.org\/10.1210\/clinem\/dgab438.","DOI":"10.1210\/clinem\/dgab438"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_007","doi-asserted-by":"crossref","unstructured":"Reinehr, T, Rothermel, J, Wegener-Panzer, A, Hartmann, MF, Wudy, SA, Holterhus, PM. Vanishing 17-Hydroxyprogesterone concentrations in 21-hydroxylase deficiency. Horm Res Paediatr 2018;90:138\u201344. https:\/\/doi.org\/10.1159\/000487927.","DOI":"10.1159\/000487927"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_008","doi-asserted-by":"crossref","unstructured":"Reddy, R, Mason, M, Patel, M, Ramasamy, R. Clinical utility of serum 17-hydroxyprogesterone as a marker for medical therapy for male infertility: recommendations based on clinical scenarios. Int J Impot Res 2023;35:79\u201381. https:\/\/doi.org\/10.1038\/s41443-022-00541-z.","DOI":"10.1038\/s41443-022-00541-z"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_009","doi-asserted-by":"crossref","unstructured":"Wong, T, Shackleton, CH, Covey, TR, Ellis, G. Identification of the steroids in neonatal plasma that interfere with 17\u00a0alpha-hydroxyprogesterone radioimmunoassays. Clin Chem 1992;38:1830\u20137. https:\/\/doi.org\/10.1093\/clinchem\/38.9.1830.","DOI":"10.1093\/clinchem\/38.9.1830"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_010","doi-asserted-by":"crossref","unstructured":"Janzen, N, Peter, M, Sander, S, Steuerwald, U, Terhardt, M, Holtkamp, U, et al.. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J\u00a0Clin Endocrinol Metab 2007;92:2581\u20139. https:\/\/doi.org\/10.1210\/jc.2006-2890.","DOI":"10.1210\/jc.2006-2890"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_011","doi-asserted-by":"crossref","unstructured":"Chudleigh, J, Holder, P. Psychosocial impact of false-positive newborn screening results: a scoping review. Children 2024;11. https:\/\/doi.org\/10.3390\/children11050507.","DOI":"10.3390\/children11050507"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_012","doi-asserted-by":"crossref","unstructured":"Gurian, EA, Kinnamon, DD, Henry, JJ, Waisbren, SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 2006;117:1915\u201321. https:\/\/doi.org\/10.1542\/peds.2005-2294.","DOI":"10.1542\/peds.2005-2294"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_013","doi-asserted-by":"crossref","unstructured":"Lacey, JM, Minutti, CZ, Magera, MJ, Tauscher, AL, Casetta, B, McCann, M, et al.. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004;50:621\u20135. https:\/\/doi.org\/10.1373\/clinchem.2003.027193.","DOI":"10.1373\/clinchem.2003.027193"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_014","doi-asserted-by":"crossref","unstructured":"K\u00f6sel, S, Burggraf, S, Fingerhut, R, D\u00f6rr, HG, Roscher, AA, Olgem\u00f6ller, B. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem 2005;51:298\u2013304.","DOI":"10.1373\/clinchem.2004.042416"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_015","doi-asserted-by":"crossref","unstructured":"Seo, JY, Park, HD, Kim, JW, Oh, HJ, Yang, JS, Chang, YS, et al.. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation. J\u00a0Perinat Med 2014;42:121\u20137. https:\/\/doi.org\/10.1515\/jpm-2013-0154.","DOI":"10.1515\/jpm-2013-0154"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_016","doi-asserted-by":"crossref","unstructured":"Minutti, CZ, Lacey, JM, Magera, MJ, Hahn, SH, McCann, M, Schulze, A, et al.. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 2004;89:3687\u201393. https:\/\/doi.org\/10.1210\/jc.2003-032235.","DOI":"10.1210\/jc.2003-032235"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_017","doi-asserted-by":"crossref","unstructured":"Zhang, Q, Zhang, L, Lin, H, Cai, Z, Yan, J, Wang, Q, et al.. Evaluation of a bracketing calibration-based isotope dilution liquid chromatography\u2013tandem mass spectrometry candidate reference measurement procedure for 17\u03b1-hydroxyprogesterone in human plasma. Anal Bioanal Chem 2019;411:7095\u2013104. https:\/\/doi.org\/10.1007\/s00216-019-02086-5.","DOI":"10.1007\/s00216-019-02086-5"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_018","doi-asserted-by":"crossref","unstructured":"Wudy, SA, Hartmann, M, Svoboda, M. Determination of 17-hydroxyprogesterone in plasma by stable isotope dilution\/benchtop liquid chromatography-tandem mass spectrometry. Horm Res 2000;53:68\u201371. https:\/\/doi.org\/10.1159\/000023516.","DOI":"10.1159\/000023516"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_019","unstructured":"Joint Committee on Traceability in Laboratory Medicine (JCTLM)_17-OHP RMPs. https:\/\/www.jctlmdb.org\/#\/app\/search\/search-results?keywords=Hydroxyprogesterone&code_type=rmp [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_020","unstructured":"Joint Committee on Traceability in Laboratory Medicine (JCTLM)_17-OHP services. https:\/\/www.jctlmdb.org\/#\/app\/search\/search-results?keywords=Hydroxyprogesterone&code_type=rms [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_021","unstructured":"Reference Institute for Bioanalysis (RfB). https:\/\/www.rfb.bio\/cgi\/surveys?searchType=analyte&rv_type=all&analyte=17-OH-Progesteron&year=2024 [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_022","unstructured":"RELA\u00a0\u2013\u00a0IFCC External Quality assessment scheme for Reference Laboratories in Laboratory Medicine. https:\/\/www.dgkl-rfb.de\/ [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_023","unstructured":"International Organization of Standardization (ISO). ISO 15193:2009(E): in\u00a0vitro diagnostic medical devices\u2212measurement of quantities in samples of biological origin\u2212requirements for content and presentation of reference measurement procedures. Geneva, Switzerland: International Organization of Standardization. https:\/\/www.iso.org\/standard\/42021.html [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_024","unstructured":"International Organization of Standardization (ISO). ISO 15194:2009: in\u00a0vitro diagnostic medical devices\u2212measurement of quantities in samples of biological origin\u2212requirements for certified reference materials and the content of supporting documentation. https:\/\/www.iso.org\/standard\/42022.html [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_025","doi-asserted-by":"crossref","unstructured":"Singh, N, Taibon, J, Pongratz, S, Geletneky, C. Quantitative NMR (qNMR) spectroscopy based investigation of the absolute content, stability and isomerization of 25-hydroxyvitamin D2\/D3 and 24(R),25-dihydroxyvitamin D2 in solution phase. Sci Rep 2022;12:3014. https:\/\/doi.org\/10.1038\/s41598-022-06948-4.","DOI":"10.1038\/s41598-022-06948-4"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_026","doi-asserted-by":"crossref","unstructured":"Jaki, BU, Bzhelyansky, A, Pauli, GF. Quantitative NMR (qNMR) for pharmaceutical analysis: the pioneering work of George Hanna at the US FDA. Magn Reson Chem 2021;59:7\u201315. https:\/\/doi.org\/10.1002\/mrc.5099.","DOI":"10.1002\/mrc.5099"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_027","doi-asserted-by":"crossref","unstructured":"Nelson, MA, Waters, JF, Toman, B, Lang, BE, R\u00fcck, A, Breitruck, K, et al.. A new realization of SI for organic chemical measurement: NIST PS1 primary standard for quantitative NMR (benzoic acid). Anal Chem 2018;90:10510\u201317. https:\/\/doi.org\/10.1021\/acs.analchem.8b02575.","DOI":"10.1021\/acs.analchem.8b02575"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_028","doi-asserted-by":"crossref","unstructured":"Miller, WG. The role of analytical performance specifications in international guidelines and standards dealing with metrological traceability in laboratory medicine. Clin Chem Lab Med 2024;62:1462\u20139. https:\/\/doi.org\/10.1515\/cclm-2023-1201.","DOI":"10.1515\/cclm-2023-1201"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_029","unstructured":"European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). EFLM biological variation database\u00a0\u2013\u00a017-OHP. https:\/\/biologicalvariation.eu\/search?query=17-a-hydroxyprogesterone [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_030","unstructured":"Clinical and Laboratory Standards Institute (CLSI). C62-A. Liquid chromatography-mass spectrometry methods; approved guideline. In: CLSI document C62-A. Wayne, PA: Clinical and Laboratory Standard Institute; 2014."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_031","unstructured":"European Medicines Agency (EMA). ICH harmonised tripartite guideline. In: Validation of analytical procedures: text and methodology Q2 (R1). London: European Medicines Agency; 1995. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-q2r1-validation-analytical-procedures-text-and-methodology-step-5-first-version_en.pdf [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_032","unstructured":"Working Group 1 of the Joint Committee for Guides in Metrology (JCGM\/WG1). Evaluation of measurement data\u00a0\u2013\u00a0guide to the expression of uncertainty in measurement (GUM), (2008; GUM 1995 with minor corrections). https:\/\/www.bipm.org\/documents\/20126\/2071204\/JCGM_100_2008_E.pdf\/cb0ef43f-baa5-11cf-3f85-4dcd86f77bd6 [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_033","unstructured":"VCA: Variance component analysis. https:\/\/cran.r-project.org\/web\/packages\/VCA\/VCA.pdf [Accessed 28 Apr 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_034","doi-asserted-by":"crossref","unstructured":"Gaudl, A, Kratzsch, J, Bae, YJ, Kiess, W, Thiery, J, Ceglarek, U. Liquid chromatography quadrupole linear ion trap mass spectrometry for quantitative steroid hormone analysis in plasma, urine, saliva and hair. J\u00a0Chromatogr A 2016;1464:64\u201371. https:\/\/doi.org\/10.1016\/j.chroma.2016.07.087.","DOI":"10.1016\/j.chroma.2016.07.087"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_035","unstructured":"JCTLM and IFCC. External quality assessment scheme for reference laboratories in laboratory medicine (RELA). https:\/\/www.dgkl-rfb.de\/4Daction\/g_show_Home\/00000000000000000000 [Accessed 22 May 2025]."},{"key":"2026081408005182988_j_cclm-2025-1169_ref_036","doi-asserted-by":"crossref","unstructured":"Rauch, G, Geistanger, A, Timm, J. A new outlier identification test for method comparison studies based on robust regression. J\u00a0Biopharm Stat 2011;21:151\u201369. https:\/\/doi.org\/10.1080\/10543401003650275.","DOI":"10.1080\/10543401003650275"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_037","doi-asserted-by":"crossref","unstructured":"Westwood, S, Lippa, K, Shimuzu, Y, Lalerle, B, Saito, T, Duewer, D, et al.. Methods for the SI-traceable value assignment of the purity of organic compounds (IUPAC Technical Report). Pure Appl Chem 2023;95:1\u201377. https:\/\/doi.org\/10.1515\/pac-2020-0804.","DOI":"10.1515\/pac-2020-0804"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_038","doi-asserted-by":"crossref","unstructured":"Lo, CWS, Hoad, K, Loh, TP, van den Berg, S, Cooke, BR, Greaves, RF, et al.. Endogenous isobaric interference on serum 17 hydroxyprogesterone by liquid chromatography-tandem mass spectrometry methods. Clin Chem Lab Med 2022;61:e64\u20136. https:\/\/doi.org\/10.1515\/cclm-2022-1086.","DOI":"10.1515\/cclm-2022-1086"},{"key":"2026081408005182988_j_cclm-2025-1169_ref_039","doi-asserted-by":"crossref","unstructured":"Ho, CS, Hoad, K, Cooke, BR, Andersen, T, Graham, P, van den Berg, SA, et al.. Ensuring quality in 17OHP mass spectrometry measurement: an international study assessing isomeric steroid interference. Clin Chem Lab Med 2024;62:911\u201318. https:\/\/doi.org\/10.1515\/cclm-2023-0864.","DOI":"10.1515\/cclm-2023-0864"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1169\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:02:08Z","timestamp":1786694528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1169\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,5,26]]}},"alternative-id":["10.1515\/cclm-2025-1169"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-1169","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}